Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts 169
WHAT IS NEW?
Year : 2014  |  Volume : 5  |  Issue : 2  |  Page : 195-199

Perampanel: New drug for treatment of refractory partial onset seizures


Department of Pharmacology, Armed Forces Medical College, Pune, Maharashtra, India

Correspondence Address:
Santosh Kumar Singh
Department of Pharmacology, Armed Forces Medical College, Sholapur Road, Pune - 411 040, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0975-9727.135796

Rights and Permissions

Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile hydrate) is the latest antiepileptic drugs for treatment of refractory partial onset seizures. Perampanel inhibits α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-induced increase in intracellular Ca 2+ and selectively blocks AMPA receptor-mediated synaptic trans­mission, thus reducing neuronal excitation. Three Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated the efficacy and good tolerability of perampanel as adjunctive treatment in patients with refractory partial-onset seizures. The drug is approved for use in the European Union and United States. The pharmacology of perampanel offers potential as more than just another new antiepileptic drug. This first-in-class drug will provide another option for practitioners of rational polytherapy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed6034    
    Printed102    
    Emailed1    
    PDF Downloaded628    
    Comments [Add]    

Recommend this journal